Summary
The proliferative rate in normal breast epithelium from 58 women undergoing reduction mammoplastics was studied using the formalin resistant antibody Ki-S5, and related to age at operation, menstrual cycle phase, family history of breast cancer, height and weight, parity, and hormonal use.
The breast tissue from women operated on in the luteal menstrual cycle phase (day 15–28 among oral contraceptive (OC) users) had significantly higher proliferative rate than breast tissue removed from women in the follicular phase (day 1–14) (p = 0.01). Among women presently exposed to hormones, those with a positive family history of breast cancer among first and second degree relatives had significantly higher values than cases without such history (p = 0.02). Weight was not significantly related to proliferation rate, while a short height was associated with a significantly higher proliferation rate (p = 0.04). Women who used OCs before the first full-term pregnancy (FFTP) had a significantly higher proliferation rate compared with never users or late users (p = 0.04). No significant difference was seen between parous versus nulliparous women.
The results from the univariate analysis persisted in multivariate models. An especially high proliferation rate was seen in young women with both a positive family history and present hormonal use (p = 0.001). Overall, it was found that young women had a non-significantly higher proliferation rate than older women (p = 0.10). Due to small sample size, these results must be regarded as preliminary, especially in the subgroup analyses.
This is a preview of subscription content, log in via an institution to check access.
References
Preston-Martin S, Pike MC, Ross RK, Jones PA, Henderson BE: Increased cell division as a cause of human cancer. Cancer Research 50: 7415–7421, 1990
Christov K, Chew KL, Ljung BM, Waldman FM, Duarte L, Goodson WH III, Smith HS, Mayall BH: Proliferation of normal breast epithelial cells as shown byin vivo labeling with bromodeoxyuridine. Am J Pathol 138: 1371–1377, 1991
Meyer JS, McDivitt RW, Stone KR, Prey MU: Practical breast carcinoma cell kinetics: review and update. Breast Cancer Research and Treatment 4: 79–88, 1984
Going JJ, Anderson TJ, Battersby S, MacIntyre CCA: Proliferative and secretory activity in human breast during natural and artificial menstrual cycles. Am J Pathol 130: 193–204, 1988
Ferguson DJP, Anderson TJ: Morphological evaluation of cell turnover in relation to the menstrual cycle in the ‘resting’ human breast. Br J Cancer 44: 177–181, 1981
Longman SM, Buehring GC: Oral contraceptives and breast cancer.In vitro effect of steroids on human mammary cell growth. Cancer 59: 281–287, 1987
Potten CS, Watson RJ, Williams GT, Tickle S, Roberts SA, Harris M, Howell A: The effect of age and the menstrual cycle upon proliferative activity of the normal human breast. Br J Cancer 58: 163–170, 1988
Anderson T, Battersby S, King R, McPherson K, Going JJ: Oral contraceptive use influences resting breast proliferation. Hum Pathol 20: 1139–1144, 1989
Kreipe H, Wacker HH, Heidebrecht HJ, Haas K, Hauberg M, Tiemann M, Parwaresch R: Determination of the growth fraction in non-Hodgkin's lymphomas by monoclonal antibody Ki-S5 directed against a formalin-resistant epitope of the Ki-67 antigen. Am J Pathol 142: 1689–1694, 1993
Williams G, Anderson E, Howell A, Watson R, Coyne J, Roberts SA, Potten CS: Oral contraceptive (OCP) use increases proliferation and decreases oestrogen receptor content of epithelial cells in the normal human breast. Int J Cancer 48: 206–210, 1991
Longacre TA, Bartow SA: A correlative morphological study of human breast and endometrium in the menstrual cycle. Am J Surg Pathol 10: 382–393, 1986
Olsson H, Möller TR, Ranstam J: Early oral contraceptive use and breast cancer among premenopausal women: final report from a study in southern Sweden. J Natl Cancer Inst 81: 1000–1004, 1989
Dupont WD, Page DL: Risk factors for breast cancer in women with proliferative disease. N Engl J Med 312: 146–151, 1985
Murray PP, Stadel BV, Schesselman JJ: Oral contraceptive use in women with a family history of breast cancer. Obstet Gynecol 73: 977–983, 1989
Miki Y, Swensen J, Shattuck-Eidens D, Futreal PA, Harshman K, Tavtigian S, Liu Q, Cochran C, Bennett LM, Ding W, Bell R, Rosenthal J, Hussey C, Tran T, McClure M, Frye C, Hattier T, Phelps R, Haugen-Strano A, Katcher H, Yakumo K, Gholami Z, Shaffer D, Stone S, Bayer S, Wray C, Bogden R, Dayananth P, Ward J, Tonin P, Narod S, Bristow PK, Norris FH, Helvering L, Morrison P, Rosteck P, Lai M, Barrett JC, Lewis C, Neuhausen S, Cannon-Albright L, Goldgar D, Wiseman R, Kamb A, Skolnick MH: Isolation of BRCA 1, the 17q-linked breast and ovarian cancer susceptibility gene. Science 266: 66–71, 1994
Futreal P, Liu Q, Shattuck-Eidens D, Cochran C, Harshman K, Tavtigian S, Bennett LM, Haugen-Strano A, Swensen J, Miki Y, Eddington K, McClure M, Frye C, Weaver-Feldhaus J, Ding W, Gholami Z, Söderkvist P, Terry L, Jhanwar S, Berchuck A, Iglehart JD, Marks J, Ballinger DG, Barrett JC, Skolnick MH, Kamb A, Wiseman R: BRCA 1 mutations in primary breast and ovarian carcinomas. Science 266: 120–121, 1994
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Olsson, H., Jernström, H., Alm, P. et al. Proliferation of the breast epithelium in relation to menstrual cycle phase, hormonal use, and reproductive factors. Breast Cancer Res Tr 40, 187–196 (1996). https://doi.org/10.1007/BF01806214
Issue Date:
DOI: https://doi.org/10.1007/BF01806214